Part 1: Practical Considerations For Venetoclax in AML

Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.

Related Content:

Targeted Therapy Treatment Innovations in AMLHematology

FDA Approves Tibsovo for Individuals Newly Diagnosed With IDH1-mutated AML

Expert: Cell, Gene Therapy Research Has Weathered the Storm of COVID-19, Leaving a Bright Future Ahead

HIV Remission Achieved in Patient Who Underwent Specialized Stem Cell Transplant